Survey Finds GLP-1 Users Cut Food Costs Nearly 30%

Sunlight.com's national survey shows Americans taking GLP-1s are spending hundreds less each month on food — and still saving even after prescription costs

KIRKLAND, Wash., Sept. 26, 2025 /PRNewswire/ -- A new report from Sunlight.com finds that Americans using GLP-1 medications such as Ozempic and Wegovy are not only losing weight, but also significantly reducing their household food spending. The study, which surveyed 1,200 current GLP-1 users in September 2025, shows average monthly food and diet-related costs fell $218 per month — nearly 30 percent.

The drop in spending was consistent across food-related categories. Respondents reported trimming their grocery bills from $351 to $282, reducing spending on restaurants and bars from $183 to $127, and cutting fast food and snack purchases from $183 to $106. Additionally, spending on diet programs declined, from $95 to $78, while fitness expenses remained virtually unchanged.

When factoring in the average out-of-pocket cost of GLP-1s, which respondents reported at $176 per month, the majority of users still came out ahead financially. On average, people netted a savings of about $42 each month, or more than $500 annually.

The survey also revealed that cost savings were part of the motivation for some patients. One in three respondents said they considered potential savings when deciding to start a GLP-1 prescription, with Gen Z adults especially likely to cite financial reasons alongside health outcomes.

"It's certainly the new GLP-1 economy as we call it," says Dr. Angela Tran. "On average, GLP-1s can lead to 15% or more body weight reduction, and for those who have lived with obesity for years, their lives will change dramatically. GLP-1s lead to less spending on food, with users eating smaller portions, cutting unnecessary snacking, finding fast food less appealing, and experiencing reduced cravings for high-sugar foods."

Methodology
Sunlight.com's survey was conducted in September 2025 via the Pollfish platform. It included 1,200 U.S. adults currently using GLP-1 medications. Screening ensured active GLP-1 use, and Pollfish applied quality controls. The margin of error is ±3 percentage points at a 95 percent confidence level.

About Sunlight
Sunlight.com empowers individuals in their weight loss journey through personalized, compassionate care and scientifically backed solutions.

SOURCE Sunlight